Sandra A Springer1, Frederick L Altice2, Maua Herme3, Angela Di Paola3. 1. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States. Electronic address: sandra.springer@yale.edu. 2. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, 135 College St., Suite 323, New Haven, CT 06510, United States. 3. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States.
Abstract
BACKGROUND: HIV-infected prisoners have a high prevalence of alcohol use disorders and commonly relapse to alcohol soon after release to the community which is linked to high morbidity, poor antiretroviral therapy (ART) adherence and increased sexual risk-taking behaviors. Extended-release naltrexone (XR-NTX) effectively reduces relapse to alcohol in alcohol dependent persons, yet it remains unexamined among criminal justice system (CJS) populations transitioning to the community. METHODS: A randomized double-blind, placebo-controlled trial of XR-NTX to improve HIV treatment outcomes via reducing relapse to alcohol use after prison release for HIV-infected hazardous drinking and alcohol dependent prisoners is discussed. RESULTS: Acceptability of study participation is high with 86% of those referred who met eligibility criteria and 85% of those who were able to receive injections prior to release accepted injections, yet important implementation issues are identified and addressed during the study and are discussed in this paper. CONCLUSION: Medication-assisted therapies for prevention of relapse to alcohol use for CJS populations transitioning to the community, especially for HIV-infected patients, are urgently needed in order to reduce alcohol relapse after release and improve HIV treatment outcomes and contribute to improved individual and public health. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:HIV-infected prisoners have a high prevalence of alcohol use disorders and commonly relapse to alcohol soon after release to the community which is linked to high morbidity, poor antiretroviral therapy (ART) adherence and increased sexual risk-taking behaviors. Extended-release naltrexone (XR-NTX) effectively reduces relapse to alcohol in alcohol dependent persons, yet it remains unexamined among criminal justice system (CJS) populations transitioning to the community. METHODS: A randomized double-blind, placebo-controlled trial of XR-NTX to improve HIV treatment outcomes via reducing relapse to alcohol use after prison release for HIV-infected hazardous drinking and alcohol dependent prisoners is discussed. RESULTS: Acceptability of study participation is high with 86% of those referred who met eligibility criteria and 85% of those who were able to receive injections prior to release accepted injections, yet important implementation issues are identified and addressed during the study and are discussed in this paper. CONCLUSION: Medication-assisted therapies for prevention of relapse to alcohol use for CJS populations transitioning to the community, especially for HIV-infectedpatients, are urgently needed in order to reduce alcohol relapse after release and improve HIV treatment outcomes and contribute to improved individual and public health. Published by Elsevier Inc.
Authors: Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler Journal: J Clin Psychopharmacol Date: 2007-10 Impact factor: 3.153
Authors: Karl Mann; Tagrid Lemenager; Sabine Hoffmann; Iris Reinhard; Derik Hermann; Anil Batra; Michael Berner; Norbert Wodarz; Andreas Heinz; Michael N Smolka; Ulrich S Zimmermann; Stefan Wellek; Falk Kiefer; Raymond F Anton Journal: Addict Biol Date: 2012-12-12 Impact factor: 4.280
Authors: Susanne Hartmann; Steina Aradottir; Marc Graf; Gerhard Wiesbeck; Otto Lesch; Katrin Ramskogler; Manfred Wolfersdorf; Christer Alling; Friedrich Martin Wurst Journal: Addict Biol Date: 2007-03 Impact factor: 4.280
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley Journal: Alcohol Clin Exp Res Date: 2008-11-25 Impact factor: 3.455
Authors: Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Panagiotis Vagenas; Shan-Estelle Brown; Jesse L Clark; Kelika A Konda; Javier R Lama; Jorge Sánchez; Ann C Duerr; Frederick L Altice Journal: Subst Use Misuse Date: 2017-02-07 Impact factor: 2.164
Authors: Panagiotis Vagenas; Angela Di Paola; Maua Herme; Thomas Lincoln; Daniel J Skiest; Frederick L Altice; Sandra A Springer Journal: J Subst Abuse Treat Date: 2014-03-12
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Archana Krishnan; Frederick L Altice Journal: Drug Alcohol Depend Date: 2017-03-10 Impact factor: 4.492
Authors: Enrico G Ferro; Damian Weikum; Panagiotis Vagenas; Michael M Copenhaver; Pedro Gonzales; Jesus Peinado; Robinson Cabello; Javier R Lama; Jorge Sanchez; Frederick L Altice Journal: AIDS Care Date: 2014-10-03
Authors: Jamie P Morano; Alexei Zelenev; Andrea Lombard; Ruthanne Marcus; Britton A Gibson; Frederick L Altice Journal: J Community Health Date: 2014-10
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731